# Kraig Biocraft Laboratories, Inc.: overview KBLB · OTC · CIK 1413119 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kblb.md) · [Financials](/companies/kblb/financials.md) · [Filings](/companies/kblb/filings.md) · [Insiders](/companies/kblb/insiders.md) Latest reported revenue: [$0](/filings/0001493152-21-019530.md) for Q2 FY2021, three months to 2021-06-30, from the 10-Q filed Aug 12, 2021 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-21-019530). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001493152-25-021953.md) | not reported | [0.00](/filings/0001493152-26-023130.md) | [0.00](/filings/0001493152-26-037818.md) | [0.00](/filings/0001493152-25-021953.md) | not reported | [0.00](/filings/0001493152-26-023130.md) | [0.00](/filings/0001493152-26-037818.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(462) d](/filings/0001493152-25-021953.md) | [(451) d](/filings/0001493152-26-013630.md) | [(544)](/filings/0001493152-26-023130.md) | [(627) d](/filings/0001493152-26-037818.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-22-006989.md) | [0.00](/filings/0001493152-24-012404.md) | [0.00](/filings/0001641172-25-001238.md) | [0.00](/filings/0001493152-26-013630.md) | [0.00](/filings/0001493152-26-013630.md) | | Free cash flow | $k | [(1,898)](/filings/0001493152-23-009476.md) | [(1,892)](/filings/0001493152-24-012404.md) | [(1,251)](/filings/0001641172-25-001238.md) | [(1,843)](/filings/0001493152-26-013630.md) | [(1,794)](/filings/0001493152-26-013630.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kblb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [McIlrath & Eck, LLC](/funds/1701714.md) | 2026-03-31 | $1.4k | 12,952 | | Not compared | ## Recent filings [All 375 filings](/companies/kblb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:31 ET | [10-Q](/filings/0001493152-26-037818.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037818 | | 2026-05-14 | 16:31 ET | [10-Q](/filings/0001493152-26-023130.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023130 | | 2026-03-30 | 17:38 ET | [10-K](/filings/0001493152-26-013630.md) | Annual report, period 2025-12-31 | 0001493152-26-013630 | | 2026-02-18 | 11:17 ET | [8-K](/filings/0001493152-26-007295.md) | 8.01 Other events | 0001493152-26-007295 | | 2025-11-12 | 16:31 ET | [10-Q](/filings/0001493152-25-021953.md) | Quarterly report, period 2025-09-30 | 0001493152-25-021953 | | 2025-08-14 | 16:01 ET | [10-Q](/filings/0001493152-25-011968.md) | Quarterly report, period 2025-06-30 | 0001493152-25-011968 | | 2025-05-15 | 16:30 ET | [10-Q](/filings/0001641172-25-010985.md) | Quarterly report, period 2025-03-31 | 0001641172-25-010985 | | 2025-03-28 | 16:46 ET | [10-K](/filings/0001641172-25-001238.md) | Annual report, period 2024-12-31 | 0001641172-25-001238 | | 2025-02-14 | 12:11 ET | [S-1/A](/filings/0001493152-25-006667.md) | Registration statement, amended | 0001493152-25-006667 | | 2025-02-13 | 17:21 ET | [S-1/A](/filings/0001493152-25-006482.md) | Registration statement, amended | 0001493152-25-006482 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013630.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1413119 - Tickers: KBLB - Exchange: OTC - SIC code: 2820 Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) - State of incorporation: WY - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.